At the news
? NEUTRALIMPACT 4/10 6-K filed Aug 3, 2026 at 07:02 ET
Compugen reported Q2 2026 results broadly in line with expectations. Revenue rose 35% YoY to $4.8M (H1) driven by Gilead license recognition, while net loss remained flat at ~$14.7M. Pipeline milestones unchanged: MAIA-ovarian PFS data expected Q1 2027, rilvegostomig OS data presented at ASCO, and GS-0321 Phase 1 on track. Cash position of $125.3M with no debt provides runway into 2029, reducing near-term financing risk.
- Cash and marketable securities of $125.3M as of June 30, 2026, with no debt and runway into 2029
- MAIA-ovarian interim PFS analysis for COM701 expected by Q1 2027
- Rilvegostomig (AZ-partnered) showed first OS readout: median 16.8 months in 1L biliary tract cancer
- GS-0321 (Gilead-partnered) Phase 1 dose-escalation continuing as planned
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access